H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on ANAB stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar’s rating is based on the promising results from AnaptysBio’s recent clinical trials and the potential long-term impact of their drug, rosnilimab. The Week 38 Phase 2b data for rheumatoid arthritis (RA) showed consistent and durable responses, supporting less frequent maintenance dosing options that could differentiate it from current standard of care treatments. This suggests that rosnilimab may offer a unique and potentially superior treatment option for RA due to its novel mechanism of action and clean safety profile.
Furthermore, the successful completion of patient enrollment in the Phase 2 ulcerative colitis (UC) trial adds to the company’s positive outlook. The trial is evaluating the efficacy of rosnilimab at different dose levels, with results expected in the fourth quarter of 2025. The potential for a global partnership or advancement to Phase 3 studies, depending on the UC trial outcomes, also contributes to the Buy rating, as it indicates the company’s strategic planning for future growth and development.